DIO Inteligência raises R$4M seed for dental X-ray AI
What's the deal? DIO Inteligência, a Brazilian healthtech that uses artificial intelligence to analyse dental X-rays, has raised R$4M in a seed round led by Triaxis CapitalDealroom has a profile for this one. Try Dealroom → and Crescera CapitalDealroom has a profile for this one. Try Dealroom →. Renato VellosoDealroom has a profile for this one. Try Dealroom →, co-founder of OdontoprevDealroom has a profile for this one. Try Dealroom → and former chief executive officer of dr.Consulta, also invested. The round drew from Criatec IV, a R$300M fund co-managed by Triaxis and Crescera with backing from Brazil's national development bank BNDES.
Founded in 2020 by Brazilian Caio Mathias and Estonian Ra Ringvee, DIO built software that scans dental radiographs and delivers diagnoses — from cavities to oral cancer — in 10 to 15 seconds, with roughly 90% accuracy. The platform also generates standardised treatment recommendations and visual reports, helping dentists communicate findings to patients.
"It's like a Waze for dentistry," said Mathias, DIO's chief operating officer.
Why now? DIO has grown its clinic base six-fold since 2024 to 1,500 clinics and currently generates R$340,000 in monthly revenue. It aims to reach 3,000 clinics by the end of 2026 and grow monthly revenue to roughly R$1.4M within 18 months. The company also plans to expand into health insurance operators, targeting audits and predictive models, alongside exploring international markets.
Velloso, a dentist by training, pointed to a large unmet need. "Only 60% of Brazil's population has access to dentistry, and most treatments aren't converted," he said. "The software shows the dentist everything that needs to be done, quickly and easily."
What could go wrong? Dental AI diagnostics face regulatory scrutiny and the challenge of gaining clinician trust. A 90% accuracy rate, while impressive, still means one in ten analyses may miss or misidentify conditions — a margin that matters in healthcare. Scaling from 1,500 to 3,000 clinics also requires significant sales and onboarding effort in a fragmented market where many practices still rely on manual interpretation.
The signal: Dealroom classifies DIO as an "early growth" stage company, suggesting its traction across 1,500 clinics has moved it beyond pure experimentation. The backing of the Criatec IV fund — a R$300M vehicle supported by Brazil's national development bank BNDES — underscores growing institutional appetite for AI-driven healthtech in Latin America, particularly in a market where fragmented dental care and low treatment conversion rates create a clear opening for standardised diagnostic tools.
Read more: neofeed.com.br
